- CRS Publications
- News
News
Authors:
Date:
PRNewswire: March 21, 2017 – NEW YORK, NY, U.S.A. and SYDNEY, Australia – EnGeneIC Limited today announced that it has begun dosing patients in a U.S.-based open-label phase 1 clinical trial evaluating its proprietary EDV™ nanocells to treat recurrent glioblastoma multiforme (GBM) in adults.
GBM…
Authors:
Date:
PRNewswire: March 21, 2017 – LEXINGTON, MA, U.S.A. – Pulmatrix, Inc. (NASDAQ: PULM), a clinical stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary diseases, today announced that it has received a key patent from the European Union.
“This new patent…
Authors:
Date:
PRNewswire: March 21, 2017 – MISSISSAUGA, ON, Canada – Crescita Therapeutics Inc. (TSX: CTX) (Crescita or the company), a commercial dermatology company with a portfolio of non-prescription skincare products and prescription drug products for the treatment and care of skin conditions and diseases…
Authors:
Date:
Business Wire: March 20, 2017 – HEIDELBERG, Germany – Novaliq, a specialty pharmaceutical company with a disruptive drug delivery platform that transforms poorly soluble drugs into effective therapeutics for ophthalmology, today announced a strategic licensing agreement with AFT Pharmaceuticals (…
Authors:
Date:
Business Wire: March 15, 2017 – BEDFORD, MA, U.S.A. – Ocular Therapeutix, Inc. (NASDAQ: OCUL), a biopharmaceutical company focused on the development, manufacturing, and commercialization of innovative therapies for diseases and conditions of the eye, today announced positive results of a patient…
Authors:
Date:
PRNewswire: March 14, 2017 – MOUNT OLIVE, NJ, U.S.A. – Flowonix Medical Inc. of New Jersey and Colorado-based Cerebral Therapeutics, announced today the first patients implanted with the Prometra® II programmable infusion system in the Australian Direct Drug Administration for Refractory Epilepsy (…
